Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Molecular Subtypes of Prostate Cancer
by
Arora, Kaveri
, Barbieri, Christopher E
in
Metastases
/ Prostate cancer
/ Taxonomy
2018
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Molecular Subtypes of Prostate Cancer
by
Arora, Kaveri
, Barbieri, Christopher E
in
Metastases
/ Prostate cancer
/ Taxonomy
2018
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Molecular Subtypes of Prostate Cancer
2018
Request Book From Autostore
and Choose the Collection Method
Overview
Purpose of ReviewThis review will examine the taxonomy of PCa subclasses across disease states, explore the relationship among specific alterations, and highlight current clinical relevance.Recent FindingsProstate cancer (PCa) is driven by multiple genomic alterations, with distinct patterns and clinical implications. Alterations occurring early in the timeline of the disease define core subtypes of localized, treatment-naive PCa. With time, an increase in number and severity of genomic alterations adds molecular complexity and is associated with progression to metastasis. These later events are not random and are influenced by the underlying subclasses.SummaryAll the subclasses of localized disease initially respond to androgen deprivation therapy (ADT), but with progression to castrate-resistant PCa (CRPC), mechanisms of resistance against ADT shift the molecular landscape. In CRPC, resistance mechanisms largely define the biology and sub-classification of these cancers, while clinical relevance and opportunities for precision therapy are still being defined.
Publisher
Springer Nature B.V
Subject
This website uses cookies to ensure you get the best experience on our website.